Cargando…

Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study

INTRODUCTION: The aim of the study was to compare glycemic and weight change outcomes for type 2 diabetes patients treated with either exenatide once-weekly (EQW) or exenatide twice-daily (EBID) with those patients treated with basal insulin (BI). METHODS: Retrospective data (2010–2014) were extract...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgan, Christopher Ll., Qiao, Qing, Grandy, Susan, Johnsson, Kristina, Jenkins-Jones, Sara, Holden, Sarah, Currie, Craig J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801245/ https://www.ncbi.nlm.nih.gov/pubmed/29318537 http://dx.doi.org/10.1007/s13300-017-0359-z

Ejemplares similares

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Kayaniyil, Sheena, et al.
Publicado: (2016)

Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study
por: Holden, Sarah E., et al.
Publicado: (2016)

Impact of differing glucose‐lowering regimens on the pattern of association between glucose control and survival
por: Currie, Craig J., et al.
Publicado: (2017)

Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin
por: Holden, Sarah E, et al.
Publicado: (2011)

The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes
por: Retnakaran, Ravi, et al.
Publicado: (2023)

Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care
por: Nunes, Anthony P., et al.
Publicado: (2017)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
por: Ponirakis, Georgios, et al.
Publicado: (2020)

Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
por: Zheng, Dan, et al.
Publicado: (2009)

Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness
por: Taylor, Simeon I., et al.
Publicado: (2023)

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
por: Davies, M J, et al.
Publicado: (2009)

The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010)
por: Holden, Sarah E, et al.
Publicado: (2013)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
por: Tobin, G S, et al.
Publicado: (2012)

Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study
por: Morgan, Christopher Ll., et al.
Publicado: (2019)

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
por: Du, Xuan, et al.
Publicado: (2018)

Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable‐drug‐naïve elderly or renal impaired patients with type 2 diabetes in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018)

Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018)

Exenatide improves glucocorticoid-induced glucose intolerance in mice
por: Zhao, Ruiying, et al.
Publicado: (2011)

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2010)

A real‐world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672)
por: Stryker, Matthew D., et al.
Publicado: (2017)

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
por: Sarkar, Gayatri, et al.
Publicado: (2014)

Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study
por: Morgan, Christopher Ll, et al.
Publicado: (2013)

The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial
por: Retnakaran, Ravi, et al.
Publicado: (2022)

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
por: Ghazi, Tara, et al.
Publicado: (2014)

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
por: Secnik Boye, Kristina, et al.
Publicado: (2006)

The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp
por: Wu, Hui, et al.
Publicado: (2014)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
por: Blevins, Thomas, et al.
Publicado: (2016)

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
por: Lundkvist, Per, et al.
Publicado: (2017)

Non-Response to Antibiotic Treatment in Adolescents for Four Common Infections in UK Primary Care 1991–2012: A Retrospective, Longitudinal Study
por: Berni, Ellen, et al.
Publicado: (2016)

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
por: Mathieu, Chantal, et al.
Publicado: (2013)

Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
por: Bai, Chuanmin, et al.
Publicado: (2022)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
por: Arnolds, Sabine, et al.
Publicado: (2010)

Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial
por: Xu, Shaoyong, et al.
Publicado: (2016)

Can exenatide flatten the post-prandial glucose curve in type 1 diabetes?
por: Boughton, Charlotte K., et al.
Publicado: (2020)

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
por: Currie, Craig J., et al.
Publicado: (2013)

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
por: Kiiskinen, Urpo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d581tgmnso86nei2jvfatb460p